Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 06 2020
03 06 2020
Historique:
received:
27
08
2019
accepted:
30
04
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Studies published in recent years have demonstrated that abnormal long noncoding RNA (lncRNA) antisense RNA to TP73 gene (TP73-AS1) expression is markedly associated with tumorigenesis, cancer progression and the prognosis of cancer patients. We aimed to explore the prognostic value of TP73-AS1 in multiple cancers. We comprehensively searched PubMed, Embase, Web of Science and the Cochrane Library (up to February 21, 2019). Hazard ratios (HRs), odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs) were calculated to estimate the association of TP73-AS1 with survival and clinicopathological features. The potential targets and pathways of TP73-AS1 in multiple cancers were summarized. Nineteen studies that involved thirteen types of cancers and 1329 cancer patients were identified as eligible for this meta-analysis. The results showed that high TP73-AS1 expression was significantly correlated with shorter overall survival (OS) (HR = 1.962, 95% CI 1.630-2.362) and disease-free survival (DFS) (HR = 2.050, 95% CI 1.293-3.249). The summary HRs of OS were 2.101 (95% CI 1.516-2.911) for gastric cancer (GC) and 1.920 (95% CI 1.253-2.942) for osteosarcoma. Subgroup analysis of OS demonstrated that the differential expression of TP73-AS1 in cancer tissues was a potential source of heterogeneity. Furthermore, increased TP73-AS1 expression was markedly associated with larger tumor size (OR = 2.759, 95% CI 1.759-4.330), advanced histological grade (OR = 2.394, 95% CI 1.231-4.656), lymph node metastasis (OR = 2.687, 95% CI 1.211-5.962), distant metastasis (OR = 4.145, 95% CI 2.252-7.629) and advanced TNM stage (OR = 2.633, 95% CI 1.507-4.601). The results of Egger's test and sensitivity analysis verified the robustness of the original results. High TP73-AS1 expression can predict poor survival and poor clinicopathological features in cancer patients and TP73-AS1 might be a potential biomarker and therapeutic target.
Identifiants
pubmed: 32493915
doi: 10.1038/s41598-020-65726-2
pii: 10.1038/s41598-020-65726-2
pmc: PMC7271165
doi:
Substances chimiques
RNA, Long Noncoding
0
Tumor Protein p73
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9053Références
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J Clin 69, 7–34, https://doi.org/10.3322/caac.21551 (2019).
doi: 10.3322/caac.21551
pubmed: 30620402
pmcid: 30620402
Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66, 271–289, https://doi.org/10.3322/caac.21349 (2016).
doi: 10.3322/caac.21349
Schmitt, A. M. et al. An inducible long noncoding RNA amplifies DNA damage signaling. Nature genetics 48, 1370–1376, https://doi.org/10.1038/ng.3673 (2016).
doi: 10.1038/ng.3673
pubmed: 27668660
pmcid: 5083181
Khorkova, O., Hsiao, J. & Wahlestedt, C. Basic biology and therapeutic implications of lncRNA. Advanced drug delivery reviews 87, 15–24, https://doi.org/10.1016/j.addr.2015.05.012 (2015).
doi: 10.1016/j.addr.2015.05.012
pubmed: 26024979
pmcid: 4544752
Huang, D. et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nature immunology 19, 1112–1125, https://doi.org/10.1038/s41590-018-0207-y (2018).
doi: 10.1038/s41590-018-0207-y
pubmed: 30224822
Sun, T. T. et al. LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. Cancer discovery 6, 784–801, https://doi.org/10.1158/2159-8290.Cd-15-0921 (2016).
doi: 10.1158/2159-8290.Cd-15-0921
pubmed: 27147598
Zhang, Y. et al. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nature genetics 50, 814–824, https://doi.org/10.1038/s41588-018-0120-1 (2018).
doi: 10.1038/s41588-018-0120-1
pubmed: 29808028
pmcid: 5980762
Kaghad, M. et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809–819 (1997).
doi: 10.1016/S0092-8674(00)80540-1
Hu, H. et al. Recently Evolved Tumor Suppressor Transcript TP73-AS1 Functions as Sponge of Human-Specific miR-941. Mol Biol Evol 35, 1063–1077, https://doi.org/10.1093/molbev/msy022 (2018).
doi: 10.1093/molbev/msy022
pubmed: 29474580
pmcid: 5913670
Tuo, Z., Zhang, J. & Xue, W. LncRNA TP73-AS1 predicts the prognosis of bladder cancer patients and functions as a suppressor for bladder cancer by EMT pathway. Biochem Biophys Res Commun 499, 875–881, https://doi.org/10.1016/j.bbrc.2018.04.010 (2018).
doi: 10.1016/j.bbrc.2018.04.010
pubmed: 29625110
Li, S. et al. The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation. J Exp Clin Cancer Res 36, 51, https://doi.org/10.1186/s13046-017-0519-z (2017).
doi: 10.1186/s13046-017-0519-z
pubmed: 28403886
pmcid: 5389141
Yang, G., Song, R., Wang, L. & Wu, X. Knockdown of long non-coding RNA TP73-AS1 inhibits osteosarcoma cell proliferation and invasion through sponging miR-142. Biomed Pharmacother 103, 1238–1245, https://doi.org/10.1016/j.biopha.2018.04.146 (2018).
doi: 10.1016/j.biopha.2018.04.146
pubmed: 29864904
Yao, Y., Sun, Y., Jiang, Y., Qu, L. & Xu, Y. Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo. Biomed Pharmacother 106, 260–266, https://doi.org/10.1016/j.biopha.2018.06.045 (2018).
doi: 10.1016/j.biopha.2018.06.045
pubmed: 29966969
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16, https://doi.org/10.1186/1745-6215-8-16 (2007).
doi: 10.1186/1745-6215-8-16
pubmed: 17555582
pmcid: 1920534
Lo, C. K., Mertz, D. & Loeb, M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC medical research methodology 14, 45, https://doi.org/10.1186/1471-2288-14-45 (2014).
doi: 10.1186/1471-2288-14-45
pubmed: 24690082
pmcid: 4021422
Wang, Y., Xiao, S., Wang, B., Li, Y. & Chen, Q. Knockdown of lncRNA TP73-AS1 inhibits gastric cancer cell proliferation and invasion via the WNT/beta-catenin signaling pathway. Oncol Lett 16, 3248–3254, https://doi.org/10.3892/ol.2018.9040 (2018).
doi: 10.3892/ol.2018.9040
pubmed: 30127921
pmcid: 6096150
Peng, J. si-TP73-AS1 suppressed proliferation and increased the chemotherapeutic response of GC cells to cisplatin. Oncol Lett 16, 3706–3714, https://doi.org/10.3892/ol.2018.9107 (2018).
doi: 10.3892/ol.2018.9107
pubmed: 30127981
pmcid: 6096144
Ding, Z., Lan, H., Xu, R., Zhou, X. & Pan, Y. LncRNA TP73-AS1 accelerates tumor progression in gastric cancer through regulating miR-194-5p/SDAD1 axis. Pathol Res Pract 214, 1993–1999, https://doi.org/10.1016/j.prp.2018.09.006 (2018).
doi: 10.1016/j.prp.2018.09.006
pubmed: 30279010
Zou, Q. et al. A TP73-AS1/miR-200a/ZEB1 regulating loop promotes breast cancer cell invasion and migration. J Cell Biochem 119, 2189–2199, https://doi.org/10.1002/jcb.26380 (2018).
doi: 10.1002/jcb.26380
pubmed: 28857253
Wang, X., Yang, B., She, Y. & Ye, Y. The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem 119, 7790–7799, https://doi.org/10.1002/jcb.27158 (2018).
doi: 10.1002/jcb.27158
pubmed: 29904939
Li, X., Wang, X., Mao, L., Zhao, S. & Wei, H. LncRNA TP73AS1 predicts poor prognosis and promotes cell proliferation in ovarian cancer via cell cycle and apoptosis regulation. Mol Med Rep 18, 516–522, https://doi.org/10.3892/mmr.2018.8951 (2018).
doi: 10.3892/mmr.2018.8951
pubmed: 29750302
Chen, X. et al. LncRNA TP73-AS1 predicts poor prognosis and functions as oncogenic lncRNA in osteosarcoma. J Cell Biochem, https://doi.org/10.1002/jcb.27556 (2018).
doi: 10.1002/jcb.27556
Zhang, R., Jin, H. & Lou, F. The Long Non-Coding RNA TP73-AS1 Interacted With miR-142 to Modulate Brain Glioma Growth Through HMGB1/RAGE Pathway. J Cell Biochem 119, 3007–3016, https://doi.org/10.1002/jcb.26021 (2018).
doi: 10.1002/jcb.26021
pubmed: 28379612
Cui, X. P. et al. LncRNA TP73-AS1 sponges miR-141-3p to promote the migration and invasion of pancreatic cancer cells through the upregulation of BDH2. Biosci Rep, https://doi.org/10.1042/BSR20181937 (2019).
Liu, C., Ren, L., Deng, J. & Wang, S. LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway. Biosci Rep 39, https://doi.org/10.1042/BSR20180999 (2019).
Liu, G. et al. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway. Cell Physiol Biochem 48, 371–384, https://doi.org/10.1159/000491767 (2018).
doi: 10.1159/000491767
pubmed: 30016766
Jia, Z. et al. Long non-coding RNA TP73AS1 promotes colorectal cancer proliferation by acting as a ceRNA for miR103 to regulate PTEN expression. Gene 685, 222–229, https://doi.org/10.1016/j.gene.2018.11.072 (2019).
doi: 10.1016/j.gene.2018.11.072
pubmed: 30472379
Chen, X. et al. lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis. Cancer Manag Res 10, 2711–2727, https://doi.org/10.2147/CMAR.S166260 (2018).
doi: 10.2147/CMAR.S166260
pubmed: 30147369
pmcid: 6101015
Chen, X. et al. The Value of lncRNA HULC as a Prognostic Factor for Survival of Cancer Outcome: A Meta-Analysis. Cell Physiol Biochem 41, 1424–1434, https://doi.org/10.1159/000468005 (2017).
doi: 10.1159/000468005
pubmed: 28315877
Liang, C. et al. Long non-coding RNA CRNDE as a potential prognostic biomarker in solid tumors: A meta-analysis. Clin Chim Acta 481, 99–107, https://doi.org/10.1016/j.cca.2018.02.039 (2018).
doi: 10.1016/j.cca.2018.02.039
pubmed: 29501692
Pang, J. C. et al. KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol 20, 1021–1032, https://doi.org/10.1111/j.1750-3639.2010.00405.x (2010).
doi: 10.1111/j.1750-3639.2010.00405.x
pubmed: 20477830
Zang, W. et al. Knockdown of long non-coding RNA TP73-AS1 inhibits cell proliferation and induces apoptosis in esophageal squamous cell carcinoma. Oncotarget 7, 19960–19974, https://doi.org/10.18632/oncotarget.6963 (2016).
doi: 10.18632/oncotarget.6963
pubmed: 26799587
pmcid: 4991431
Tao, W., Sun, W., Zhu, H. & Zhang, J. Knockdown of long non-coding RNA TP73-AS1 suppresses triple negative breast cancer cell vasculogenic mimicry by targeting miR-490-3p/TWIST1 axis. Biochem Biophys Res Commun 504, 629–634, https://doi.org/10.1016/j.bbrc.2018.08.122 (2018).
doi: 10.1016/j.bbrc.2018.08.122
pubmed: 30193732
Li, X., Wang, X., Mao, L., Zhao, S. & Wei, H. LncRNA TP73-AS1 predicts poor prognosis and promotes cell proliferation in ovarian cancer via cell cycle and apoptosis regulation. Molecular medicine reports 18, 516–522, https://doi.org/10.3892/mmr.2018.8951 (2018).
doi: 10.3892/mmr.2018.8951
pubmed: 29750302
Chen, X. et al. LncRNA TP73-AS1 predicts poor prognosis and functions as oncogenic lncRNA in osteosarcoma. Journal of cellular biochemistry 120, 2569–2575, https://doi.org/10.1002/jcb.27556 (2019).
doi: 10.1002/jcb.27556
Li, Y., Jiao, Y., Hao, J., Xing, H. & Li, C. Long noncoding RNA TP73-AS1 accelerates the epithelial ovarian cancer via epigenetically repressing p 21. Am J Transl Res 11, 2447–2454 (2019).
pubmed: 31105851
pmcid: 6511761
Xiao, S., Wang, R., Wu, X., Liu, W. & Ma, S. The Long Noncoding RNA TP73-AS1 Interacted with miR-124 to Modulate Glioma Growth by Targeting Inhibitor of Apoptosis-Stimulating Protein of p53. DNA Cell Biol 37, 117–125, https://doi.org/10.1089/dna.2017.3941 (2018).
doi: 10.1089/dna.2017.3941
pubmed: 29412778
Mazor, G. et al. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis 10, 246, https://doi.org/10.1038/s41419-019-1477-5 (2019).
doi: 10.1038/s41419-019-1477-5
pubmed: 30867410
pmcid: 6416247
Cai, Y. et al. Long non-coding RNA TP73-AS1 sponges miR-194 to promote colorectal cancer cell proliferation, migration and invasion via up-regulating TGFalpha. Cancer Biomark 23, 145–156, https://doi.org/10.3233/CBM-181503 (2018).
doi: 10.3233/CBM-181503
pubmed: 30010111